PASADENA, Calif.--(BUSINESS WIRE)--Dine Brands Global, Inc. (NYSE: DIN) (the "Company†or "Dine Brands†), the parent company of Applebee's Neighborhood Grill + Bar®, IHOP® and Fuzzy's Taco Shop® restaurants, today announced financial results for the third quarter of fiscal year 2025. "In the third quarter, Dine Brands sustained positive sales and traffic trends, driven by our everyday value platforms, innovative new menu offerings, and high-impact marketing that continues to resonate with guest. ...

ROCKFORD, Mich.--(BUSINESS WIRE)--Wolverine World Wide, Inc. (NYSE: WWW) today reported financial results for the third quarter ended September 27, 2025. "We delivered a solid quarter with Merrell, Saucony, and Sweaty Betty all exceeding expectations. Our disciplined execution, coupled with another record gross margin quarter, delivered better-than-anticipated earnings per share," said Chris Hufnagel, President and Chief Executive Officer of Wolverine Worldwide. "While we are pleased with our p. ...

Core Viewpoint - Magna International Inc. has announced the renewal of its normal course issuer bid (NCIB), allowing the purchase of up to 25,300,000 common shares, which is approximately 10% of its public float, starting from November 7, 2025, and ending no later than November 6, 2026 [1][7]. Summary by Sections NCIB Details - The primary purposes of the NCIB include facilitating share purchases for cancellation and funding stock-based compensation awards [2]. - The NCIB allows purchases to be made on the Toronto Stock Exchange (TSX) and the New York Stock Exchange (NYSE), adhering to respective regulations [3]. - The maximum number of shares that can be purchased daily on the TSX is 321,966, based on 25% of the average daily trading volume over the past six months [4]. Previous NCIB - The current NCIB, which allows for the purchase of up to 28,500,000 common shares, will expire at the close of trading on November 6, 2025. As of October 31, 2025, Magna had repurchased 5,834,714 shares at average prices of C$61.21 and US$43.45 [5]. Automatic Purchase Plan - An automatic share purchase plan has been established to facilitate share purchases under the NCIB, effective November 7, 2025. This plan will operate under strict parameters to comply with regulatory restrictions [6][8].

Core Insights - Ocugen is progressing with its late-stage modifier gene therapies, targeting BLA/MAA filings in 2026 and 2027, with significant enrollment milestones achieved in ongoing clinical trials [2][3][4] Clinical Development - The OCU400 Phase 3 liMeLiGhT clinical trial is nearing completion, with 50% enrollment achieved, and is on track for BLA and MAA submissions in 2026 [3][6] - The OCU410ST Phase 2/3 GARDian3 pivotal confirmatory trial is also progressing well, with the EMA accepting a single U.S.-based trial for MAA submission [4][6] - Ocugen's gene-agnostic approach aims to treat retinitis pigmentosa (RP), which affects approximately 300,000 individuals in the U.S. and Europe, with a single therapeutic method addressing multiple genetic mutations [3][12] Licensing and Financial Agreements - Ocugen has entered an exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, which includes potential upfront and milestone payments totaling up to $7.5 million, plus sales milestones projected to reach $180 million in the first decade [2][6] - The company will receive a 25% royalty on net sales from Kwangdong and is responsible for manufacturing and supplying OCU400 [2][6] Financial Performance - For Q3 2025, Ocugen reported total revenue of $1.75 million, an increase from $1.14 million in Q3 2024, while total operating expenses rose to $19.4 million from $14.4 million in the same period [10][19] - The net loss for Q3 2025 was $20.05 million, compared to a net loss of $12.97 million in Q3 2024 [19] - As of September 30, 2025, the company had cash and cash equivalents totaling $32.9 million, down from $58.8 million at the end of 2024 [12][19] Future Outlook - Upcoming milestones include the release of full data from the OCU410 Phase 2 trial in Q1 2026, interim data from the OCU410ST trial in mid-2026, and top-line data from the OCU400 Phase 3 trial in Q4 2026 [7][12] - The company is actively pursuing additional financing and strategic partnerships to support its commercialization efforts [7]

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the "Events†page of the Investors section of the Compass website. A replay of the webcast will ...

Core Viewpoint - Perrigo Company plc is initiating a strategic review of its infant formula business to assess various alternatives and align with its 'Three-S' plan, focusing on disciplined capital allocation and improving returns [1][2][4] Business Overview - The infant formula business is projected to generate net sales of approximately $360 million in 2025, representing about 90% of Perrigo's global Nutrition category and less than 10% of the company's total annual net sales [3] - The operations have stabilized, producing quality assured formula, and Perrigo remains the only large-scale U.S. store brand and contract manufacturer with a significant near-term innovation pipeline [3] Strategic Intent - The review aims to accelerate cash flows and reassess a previously announced investment of $240 million in the infant formula business while optimizing portfolio impact [2] - The CEO emphasized the need for discipline in positioning the company's portfolio for sustainable growth and free cash flow generation, noting that the external environment has changed, affecting the strategic fit with consumer health OTC businesses [4]

Audit and tax firm Cooper Parry has increased its audit operations in London and the South, expanding its team and strengthening expertise. The firm has a national audit team of 800, with 230 professionals now working in London and the South. Recent changes include the arrival of Sarah Harries as audit director. Harries joined the firm from BDO UK in September, bringing experience in auditing law firms and partnership structures. She is knowledgeable in areas such as the UK GAAP, Solicitors Accounts Ru ...

Core Insights - Recursion has announced a leadership transition plan, effective January 1, 2026, with Chris Gibson transitioning to Chairman of the Board and Najat Khan appointed as the new CEO and President [1][2][4] Leadership Transition - The Board of Directors unanimously approved the transition, emphasizing continuity and collaboration for Recursion's future [1][2] - Chris Gibson has led the company for twelve years, transforming it into a pioneer in the TechBio sector, and will continue to provide guidance as Chairman [2][4] - Najat Khan, currently Chief R&D and Commercial Officer, has been recognized for her strategic insight and leadership, having worked closely with Gibson for the past 18 months [2][5] Najat Khan's Background - Dr. Najat Khan has a strong background in biopharma, with experience in integrating scientific discovery, data, and business strategy [3][6] - Prior to joining Recursion, she held significant roles at Johnson & Johnson, where she tripled pipeline value and advanced AI integration in R&D [6] - Khan holds a Ph.D. in Organic Chemistry and has certifications in AI/ML from MIT, showcasing her expertise in both science and technology [7] Recursion's Mission and Vision - Recursion aims to decode biology to radically improve patients' lives, leveraging its OS platform that combines biology, chemistry, and AI [8] - The company operates one of the largest proprietary biological and chemical datasets, utilizing advanced machine-learning algorithms for drug discovery [8] - Recursion's operational scale includes conducting millions of wet lab experiments weekly and managing one of the most powerful supercomputers globally [8]

My previous investment thought on Hasbro Inc. ( HAS ) was a buy rating, as I expected the business to continue delivering stronger earnings growth, which would be the catalyst to drive up multiples. I stay bullish on HAS asI focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-ter ...

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2025) - Hayasa Metals Inc. (TSXV: HAY) (OTCQB: HAYAF) ("Hayasa" or the "Company") is pleased to announce the successful completion of its 2025 drill program at the Vardenis Copper-Gold Project in central Armenia which is under option to Teck Resources Limited ("Teck", see news release dated August 27, 2025). The program, which commenced in late August and concluded on October 27, comprised 10 diamond drill holes totaling 4,561 meters, completed wi ...